Lymphoma, Non-Hodgkin: all 2,043 studies
Page 15 of 21. Open to participants first (309), then studies with results posted, then the rest; newest registration first within each.
- Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
- Response to Influenza Vaccination in Lymphoma Patients Treated With RituximabCompletedNCT01707628Not applicable
- Prospective Study of Lymphoproliferative DiseasesWithdrawnNCT01704742
- Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3
- Assessment of Impact Nutritional Program During Autologous Stem Cell TransplantTerminatedNCT01699581Phase 2
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
- An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's LymphomaCompletedNCT01684865
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/LymphomaTerminatedNCT01658007Early Phase 1
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesTerminatedNCT01643603Phase 1
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
- Studying Genes Associated With Non-Hodgkin Lymphoma in Young PatientsCompletedNCT01623856
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Osteonecroses in Pediatric Patients With ALLStatus unknownNCT01619124
- Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B PatientsCompletedNCT01613300Phase 2
- Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaTerminatedNCT01609816Phase 1
- Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CTWithdrawnNCT01598558Not applicable
- A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01594229Phase 1
- Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLTerminatedNCT01585688Phase 1/2
- Study of Lymphoma in AsiaCompletedNCT01584141
- Endomicroscopy and Gastric MALT-lymphomaCompletedNCT01583699Not applicable
- Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin LymphomaStatus unknownNCT01570049Phase 3
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin LymphomaCompletedNCT01569750Phase 1
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's LymphomasCompletedNCT01567475Phase 1
- Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters StudyCompletedNCT01565447
- PEARL Study: Improvement of Non-Hodgkin's Lymphoma CareStatus unknownNCT01562509Not applicable
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Phase I/II Study of Abraxane in Recurrent and Refractory LymphomaTerminatedNCT01555853Phase 1
- Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
- Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell TransplantationTerminatedNCT01541072Not applicable
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell LymphomaWithdrawnNCT01539174Phase 2
- Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive LymphomasCompletedNCT01538641Phase 2
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01534715Phase 1
- Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood UnitCompletedNCT01527838Phase 1
- Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHLCompletedNCT01527422Phase 1/2
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced ThrombocytopeniaCompletedNCT01516619Phase 2
- Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingNCT01494103Phase 1
- A Phase I Study of CD19 Specific T Cells in CD19 Positive MalignancyTerminatedNCT01493453Phase 1
- Functional Assessment of Cancer Therapy - Bone Marrow TransplantStatus unknownNCT01490957
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin LymphomaCompletedNCT01482754Not applicable
- Providing Access to Cord Blood Units for TransplantsWithdrawnNCT01479582Phase 2
- Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in JapanCompletedNCT01479387
- Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)TerminatedNCT01476085Phase 1
- CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
- Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT01471210Phase 1
- Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedNCT01456351Phase 3
- Zevalin Post-marketing Surveillance in JapanCompletedNCT01448928
- Study in Patients With Primary Breast Diffuse Large B-cell LymphomaCompletedNCT01448096Phase 2
- Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated DiseasesCompletedNCT01447056Phase 1
- Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01429025Phase 1
- Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
- MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
- Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic MalignanciesCompletedNCT01413568Phase 1/2
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell LymphomaCompletedNCT01410630
- Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01410513Phase 1
- Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT01403415Phase 1
- A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaCompletedNCT01392716Phase 2
- A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT01388959Phase 2
- Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT01363817Phase 1
- Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's LymphomaCompletedNCT01356173Phase 1
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
- Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTALCompletedNCT01333046Phase 1
- Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line ChemotherapyStatus unknownNCT01329354Phase 2
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin LymphomaCompletedNCT01328626Phase 1
- A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesCompletedNCT01321346Phase 1
- Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)WithdrawnNCT01316146Phase 1
- Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin LymphomaStatus unknownNCT01307592Phase 2
- AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
- Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).CompletedNCT01296256Phase 2
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin LymphomaCompletedNCT01290120Phase 2
- A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.TerminatedNCT01289223Phase 3
- PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot StudyActive, not recruitingNCT01269593Early Phase 1
- Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter PyloriCompletedNCT01264822
- Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's LymphomaCompletedNCT01230983Phase 3
- A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's LymphomaCompletedNCT01209130Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)CompletedNCT01196520
- A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001No longer availableNCT01196208
- EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ LymphomaActive, not recruitingNCT01192464Phase 1
- Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLTerminatedNCT01187810Phase 1
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)WithdrawnNCT01170052Phase 1/2
- Mozobil for Autologous Stem Cell MobilizationCompletedNCT01164345Phase 2